Project description DEENESFRITPL A novel tricuspid valve implantation procedure The tricuspid valve sits between the two right chambers of the heart and allows blood to flow in an unidirectional manner from the atrium to the ventricle. Treatment of tricuspid valve malfunction mainly involves open-heart surgery since transcatheter valve replacement is inefficient with many potential side effects. The EU-funded TriSol System project has developed a fast and minimally invasive implant procedure that facilitates the positioning of a new valve in a safe manner. The approach employs a flexible delivery system, and patients require minimal hospitalisation and recovery time. Most importantly, it reduces the high mortality rates and significant side effects of open-heart surgery. Show the project objective Hide the project objective Objective About 17 million people die each year from cardiovascular diseases (CVDs), a number that is expected to grow to more than 23 million by 2030. Of these deaths, an estimated 7.4 million were due to heart disease, including heart valve disease (HVD) such as tricuspid regurgitation (TR). The golden standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, high-risk interventions require long recovery time long in-hospital stays and have significant hospital mortality (more than 10%). Transcatheter tricuspid valve replacement (TTVR) is still ineffective due to the increased risk of side effects in right ventricle making this solution not available on the market. TriSol is introducing the TriSol System, a heart valve replacement system for treating severe TR and preventing RV dysfunction which usually follows tricuspid valve surgery. A flexible delivery system allows to position the valve into the heart through support arms for anchoring to the tricuspid physiological site. The entire procedure is performed in a medical center and takes up to 30 minutes compared to 2-4 hours of standard surgery. Trisol System will allow cardiologists to perform a quick and safe implant procedure thus increasing the number of treated population and reducing in-hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries. During the feasibility assessment, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. During the second phase of innovation project, TriSol will upgrade the valve and delivery system components of TriSol system for application in multiple valve conditions such as mitral valve regurgitation. It will also increase the production line up to 4k per year. Multiple clinical trials will then be initiated for obtaining CE mark as a medical device. Fields of science social sciencessociologydemographymortalitymedical and health sciencesclinical medicinesurgerysurgical proceduresmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesmedical biotechnologyimplants Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator TRISOL MEDICAL LTD Net EU contribution € 50 000,00 Address TAVOR BUILDING ENTRANCE 2 LEVEL 3 2069202 YOKNEAM Israel See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
